CPGJ 602

Drug Profile

CPGJ 602

Alternative Names: CPGJ602; Recombinant human-mouse chimeric anti-EGFR monoclonal antibody - Sunshine Guojian

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sunshine Guojian Pharmaceutical
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer

Most Recent Events

  • 15 Nov 2017 Phase-I clinical trials in Colorectal cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease) in China (IV) (NCT03356158)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top